OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) may derive from an intraductal papillary mucinous neoplasm (IPMN) of the pancreas or may develop in the pancreatic duct apart from IPMN. The purpose of this study was to define the clinicopathological features of these 2 entities and compare them with those of ordinary PDAC. METHODS: Of 765 patients who had surgical resection for IPMN, 122 were diagnosed as having PDAC derived from IPMN and 31 with PDAC concomitant with IPMN. In addition, 7605 patients with PDAC who were registered in the Japan Pancreas Society pancreatic cancer registry were compared with the above patients. RESULTS: Pancreatic ductal adenocarcinomas derived from IPMN and concomitant with IPMN were significantly smaller, less invasive, and less extensive than ordinary PDAC. The median survival of patients with the 2 conditions was significantly longer than for those with ordinary PDAC when compared overall or when limited to TS2 (2.0 cm < tumor size ≤ 4.0 cm) or TS3 (4.0 cm < tumor size ≤ 6.0 cm) cases. CONCLUSIONS: These findings suggest that PDAC concomitant with IPMN and PDAC derived from IPMN may have more favorable biological behaviors or be diagnosed earlier than ordinary PDAC.
OBJECTIVES:Pancreatic ductal adenocarcinoma (PDAC) may derive from an intraductal papillary mucinous neoplasm (IPMN) of the pancreas or may develop in the pancreatic duct apart from IPMN. The purpose of this study was to define the clinicopathological features of these 2 entities and compare them with those of ordinary PDAC. METHODS: Of 765 patients who had surgical resection for IPMN, 122 were diagnosed as having PDAC derived from IPMN and 31 with PDAC concomitant with IPMN. In addition, 7605 patients with PDAC who were registered in the Japan Pancreas Society pancreatic cancer registry were compared with the above patients. RESULTS:Pancreatic ductal adenocarcinomas derived from IPMN and concomitant with IPMN were significantly smaller, less invasive, and less extensive than ordinary PDAC. The median survival of patients with the 2 conditions was significantly longer than for those with ordinary PDAC when compared overall or when limited to TS2 (2.0 cm < tumor size ≤ 4.0 cm) or TS3 (4.0 cm < tumor size ≤ 6.0 cm) cases. CONCLUSIONS: These findings suggest that PDAC concomitant with IPMN and PDAC derived from IPMN may have more favorable biological behaviors or be diagnosed earlier than ordinary PDAC.
Authors: Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa Journal: Am J Surg Pathol Date: 2015-12 Impact factor: 6.394
Authors: Antonio Pea; Jun Yu; Neda Rezaee; Claudio Luchini; Jin He; Marco Dal Molin; James F Griffin; Helen Fedor; Shahriar Fesharakizadeh; Roberto Salvia; Matthew J Weiss; Claudio Bassi; John L Cameron; Lei Zheng; Aldo Scarpa; Ralph H Hruban; Anne Marie Lennon; Michael Goggins; Christopher L Wolfgang; Laura D Wood Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban Journal: Ann Surg Date: 2016-01 Impact factor: 12.969
Authors: Karolina S Jabbar; Liisa Arike; Caroline S Verbeke; Riadh Sadik; Gunnar C Hansson Journal: J Clin Oncol Date: 2017-11-22 Impact factor: 44.544